Fluconazole - Modification P00005 to Contract
Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYTROOP SUPPORT MEDICAL

Original Source

https://sam.gov/opp/c6802f6ec88646339de3697742be44a2/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY - TROOP SUPPORT MEDICAL is seeking a modification to the contract for Fluconazole. Fluconazole is a medication used to treat and prevent fungal infections. The modification, P00005, will involve changing the National Drug Codes (NDCs) associated with the procurement.

    Point(s) of Contact
    Keith Ryales
    (215) 737-9199
    keith.ryales@dla.mil
    Files
    Title
    Posted
    SPE2D221D0025 P00005 signed.pdf
    Lifecycle
    Title
    Type
    Fluconazole - Modification P00005 to Contract
    Currently viewing
    Special Notice
    Similar Opportunities
    Fluconazole - SPE2D221-D-0125-P00012 - Final Option Notice
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), has issued a special notice regarding the contract modification for Fluconazole under contract number SPE2D221-D-0125-P00012. This modification announces the exercise of the final option for the procurement of this pharmaceutical product, which is critical for various medical applications within military healthcare. Interested parties can reach out to the primary contact, Courtney Hunter-Stangler, at Courtney.Hunter-Stangler@dla.mil or by phone at 215-737-6845, or to the secondary contact, Jason Wray, at jason.wray@dla.mil or 215-737-0614, for further details regarding this opportunity.
    Fexofenadine HCL Follow On MOD P00002
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Fexofenadine HCL Follow On MOD P00001. Fexofenadine HCL is a drug used to relieve symptoms of seasonal allergies such as runny nose, sneezing, itchy or watery eyes, and itching of the nose or throat. This procurement is for NDC changes. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    LANSOPRAZOLE NATIONAL CONTRACT MODIFICATION
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is issuing a modification to the LANSOPRAZOLE NATIONAL CONTRACT. This modification aims to incorporate additional clauses to the existing contract. Lansoprazole is a medication used to treat stomach and esophagus problems such as acid reflux, ulcers, and gastroesophageal reflux disease (GERD). It belongs to a class of drugs known as proton pump inhibitors and helps reduce the amount of acid produced in the stomach. The modification to the contract will include the addition of specific clauses that may address various aspects such as pricing, delivery schedules, quality control, or any other relevant terms and conditions. For more information or inquiries, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 2157378677.
    VANCOMYCIN MODIFICATION
    Buyer not available
    Special Notice DEPT OF DEFENSE is seeking VANCOMYCIN MODIFICATION services. VANCOMYCIN MODIFICATION P00005 is a contract modification that incorporates additional clauses into the existing contract. VANCOMYCIN is an antibiotic used to treat serious bacterial infections. The DEPT OF DEFENSE is looking to modify the contract to include these additional clauses.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    MODIFICATION TO ENALAPRIL NATIONAL CONTRACT
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking a modification to the ENALAPRIL NATIONAL CONTRACT. This modification aims to incorporate additional clauses into the existing contract. The ENALAPRIL NATIONAL CONTRACT is typically used for the procurement of enalapril, a medication used to treat high blood pressure and heart failure. The modification will ensure that the contract includes all necessary terms and conditions for the procurement of enalapril. For more information, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 215-737-8677.
    Fexofenadine HCL Follow On
    Buyer not available
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Fexofenadine HCL Follow On. Fexofenadine HCL is typically used as an antihistamine to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching.
    Doxycycline Hyclate
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Doxycycline Hyclate. The contract will establish a national supply source to provide Doxycycline Hyclate 100MG Tablets in various bottle sizes. This acquisition is for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be firm-fixed price, requirements type with a one year base and four one year options. Interested parties should contact Catherine Gilbert for more information. The projected solicitation date is September 2019.
    Famotidine
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Dextroamphetamine/Amphetamine National Contract
    Buyer not available
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is a procurement notice from the DEFENSE LOGISTICS AGENCY, specifically the DLA TROOP SUPPORT office. This notice falls under the category of MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES with a PSC code of 6515. The primary contact for this contract is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 215-737-8677. The notice describes an amendment, P00006, which incorporates additional clauses to the existing contract.